LBA vs LC-MS: competing technologies at a development crossroad
The Aliri team recently hosted this webinar to discuss why so many sponsors are now reconsidering the use of Ligand-Binding Assays (LBA) for the vast majority of large molecule protein analysis given the many compelling benefits Liquid Chromatography-Mass Spectrometry (LC-MS) can provide in terms of speed, cost, and data specificity.
Watch this on-demand webinar with bioanalytical experts Shane Karnik, MS, and Matt Hartle, PhD, to learn more about the changing market landscape, pros and cons for each technology, and why you should consider LC-MS over LBA for your next large molecule program.
This webinar also explores:
• advancements in biomarker discovery, validation and quantification using LC-MS technologies, and
• complexities of analyzing transgenic expressed proteins, focusing on the differences between human and endogenous proteins, with a special emphasis on mRNA drugs.
Join our scientific rock stars to learn more!
CONTACT US to learn more about Aliri’s extensive experience with this technology.
Combining in Vivo Metabolism and Whole-Body Biodistribution for Comprehensive Insight into ERAP2 Inhibitor Pharmacokinetic
Explore our innovative research combining in vivo metabolism and whole-body biodistribution to gain comprehensive insights into the pharmacokinetics of an ERAP2 inhibitor. By comparing traditional liquid assays with advanced mass spectrometry imaging, we reveal the stability and biodistribution of the compound.
Download our poster to learn more.
Identification and Quantitation of Low-Level Dendrimer (10183 Da) in Rat Plasma Using HRAM-Mass Spectrometry
Discover our breakthrough method for identifying and quantifying low-level dendrimer (10183 Da) in rat plasma using HRAM-mass spectrometry. Dendrimers play a crucial therapeutic role, but their high molecular weight makes low-concentration detection challenging. Our research presents a reliable method to quantify these macromolecules.
Download our poster to learn more.
Antisense Oligonucleotide Extraction Optimization Reveals Significant Differences Between Non-Human Primate Spinal Cord, Mouse Spinal Cord, and Mouse Brain Tissue Homogenates
Discover the critical differences in antisense oligonucleotide (ASO) extraction methods across non-human primate spinal cord, mouse spinal cord, and mouse brain tissues. Our research highlights how unique tissue properties demand distinct extraction techniques for optimal results.
Download our poster to learn more.
LC/MS/MS Analysis of Coproporphyrin I and Coproporphyrin III in Human Plasma
A bioanalytical assay was developed and validated for the analysis of coproporphyrin I (CP‐I) and coproporphyrin III (CP‐III) in human plasma to assess hepatic OATP1B1/1B3 function. This method uses LC-MS/MS detection to monitor these biomarkers and potentially avoid the need for dedicated clinical drug-drug interaction studies. Download our poster to learn more.
Non-Proprietary Assay (NPA) List
Aliri brings more than 30 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development. We offer an extensive list of validated, off-the-shelf assays you can leverage to support a range of research applications. In addition to the hundreds of assays listed below, Aliri also excels at developing customized methods to meet your specific challenges.
The Importance of Sample Clean up Demonstrated by the Revalidation of the Biomarker 4β-hydroxycholesterol for Assay Robustness
Uncover the advancements reshaping biomarker analysis with our refined method for quantifying 4β-hydroxycholesterol (4β-OHC) – a vital biomarker for CYP3A activity. With our improved assay methodology, we offer a reliable solution for quantifying 4β-OHC, empowering researchers and clinicians with accurate biomarker data for informed treatment decisions.
Download our poster to unlock the potential of this innovative approach.
Validation of an LCMS Hybrid Assay with EVOSEP cleanup for the quantitation of Islet Amyloid polypeptide in human plasma
Delve into the forefront of biomarker analysis with our validated LCMS Hybrid Assay, offering precise quantitation of Islet Amyloid Polypeptide (IAPP) in human plasma. Our method revolutionizes detection by coupling immunoprecipitation from plasma with EVOSEP solid phase extraction and microflow chromatography, resulting in detection limits comparable to traditional methods. By leveraging a high-binding, non-specific antibody for IAPP, our assay surpasses commercially available kits, ensuring comprehensive analysis of different IAPP forms.
Download our poster to discover the innovation behind our approach and its potential uses in regulated settings and biologics advancement.
Tissue Adenosine Distribution-Guided Gene Selection for the Development of a Composite Biomarker in Immuno-Oncology Therapy
Discover the groundbreaking approach revolutionizing Immuno-Oncology (IO) therapy through tissue adenosine distribution-guided gene selection for composite biomarker development. Our method transcends traditional predictive biomarkers by integrating spatial metabolomics and genomics, offering a comprehensive strategy to predict patient responses to IO therapies.
Download our poster to explore the transformative potential of adenosine-driven gene signatures in personalized cancer treatment strategies.
Multimodal stratification of predictive biomarkers in head and neck cancers: A focus on cytokine-based immunotherapy
Explore our recent poster presentation, which discusses the challenge of identifying predictive biomarkers for cytokine-based immunotherapy in head and neck cancers due to the complexity of biological systems and cancer pathophysiology. It highlights the importance of understanding how drugs interact with different biomarkers and tissues spatially to improve trial success rates, reduce costs, and accelerate completion times.
By analyzing spatial and temporal changes in tumor cells and their microenvironment, you can uncover resistance mechanisms, leading to the design of more effective combination therapies. The Aliri solution offers enhanced tumor profiling through spatial analysis, integration of heterogenous data types, and predictive analysis, ultimately identify robust biomarker signatures for improved immunotherapy outcomes.
Download our poster to gain insights into the unique biomarker signatures correlated with therapy response.
CONTACT US to learn more about Aliri’s extensive experience with this technology.